AICARFT及mTOR在人肺腺癌亲本株A549及培美曲塞耐药株A549/PEM的表达及意义

doi:10.11904/j.issn.1002-3070.2015.04.010

实用肿瘤学杂志 ›› 2015, Vol. 29 ›› Issue (4): 337-341.doi: 10.11904/j.issn.1002-3070.2015.04.010

AICARFT及mTOR在人肺腺癌亲本株A549及培美曲塞耐药株A549/PEM的表达及意义

张丹¹ ,王红阳² ,黄艳² ,王立民²

1.华北理工大学研究生院(唐山 063000);
2.华北理工大学附属医院呼吸内科

收稿日期:2015-05-20 出版日期:2015-08-27 发布日期:2015-08-27
通讯作者: 黄艳 E-mail:amanda2003sea@163.com
作者简介:张丹,女,(1990-),硕士研究生,从事肺癌耐药机制的研究

The expression and significance of AICARFT and mTOR in pemetrexed resistant human lung adenocarcinoma cancer cell line A549/PEM

ZHANG Dan¹,WANG Hongyang²,HUANG Yan²,WANG Limin²

1.North China University of Science and Technology Graduate School,Tangshan 063000,China;
2 Department of Pulmonary Medicine,The North China University of Science and Technology Affiliated Hospital

Received:2015-05-20 Online:2015-08-27 Published:2015-08-27

摘要/Abstract

摘要： 目的探讨AICARFT、mTOR在人肺腺癌亲本株A549及培美曲塞诱导人肺腺癌耐药株A549/PEM中表达变化及意义。方法流式细胞术检测A549及A549/PEM细胞周期分布,RT-PCR、Western blot分别检测AICARFT、mTOR在A549及A549/PEM的mRNA及蛋白表达变化。结果流式细胞术检测细胞周期提示处于S期的A549/PEM较A549明显增多,分别为(36.61±1.36)%和(27.16±1.08)%(P=0.001);RT-PCR检测mRNA示A549/PEM的AICARFT及mTOR基因表达与A549相比均表达上调(P＜0.05);Western blot检测蛋白示A549/PEM的AICARFT及mTOR蛋白表达与A549相比均表达上调(P＜0.05)。结论人肺腺癌培美曲塞获得性耐药细胞株出现细胞周期重分布,培美曲塞获得性耐药可能与AICARFT、mTOR表达上调相关。

关键词: AICARFT, mTOR, 耐药, A549, A549/PEM

Abstract: Objective To investigate the expression of AICARFT and mTOR in lung adenocarcinoma cell line A549 and pemetrexed resistant human lung adenocarcinoma cell line A549/PEM.Methods The distribution of cell cycle was evaluated by flow cytometry assay.The expression of AICARFT and mTOR in A549 and A549/PEM were detected by RT-PCR and Western blot.Results Flow cytometry analysis showed that S phase in A549/PEM was higher than that in A549((36.61±1.36)% vs(27.16±1.08)%(P=0.001)).mRNA over expression of AICARFT and mTOR in A549/PEM were detected by RT-PCR(P＜0.05).Protein over expression of AICARFT and mTOR in A549/PEM were detected by Western blot.(P＜0.05).Conclusion High level of AICARFT and mTOR may be connected with pemetrexed acquired drug resistance in lung adenocarcinoma.The cycle of pemetrexed resistant human lung adenocarcinoma cancer cell line A549/PEM is redistributed.

Key words: AICARFT, mTOR, Resistant, A549, A549/PEM

中图分类号:

R734.2

张丹,王红阳,黄艳,王立民. AICARFT及mTOR在人肺腺癌亲本株A549及培美曲塞耐药株A549/PEM的表达及意义[J]. 实用肿瘤学杂志, 2015, 29(4): 337-341.

ZHANG Dan,WANG Hongyang,HUANG Yan,WANG Limin. The expression and significance of AICARFT and mTOR in pemetrexed resistant human lung adenocarcinoma cancer cell line A549/PEM[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(4): 337-341.

参考文献

1 李军,徐向英,徐建宇.培美曲塞联合放射治疗中晚期肺腺癌的临床研究[J].实用肿瘤学杂志,2015,29(2):111-115.
2 孔庆暖,傅兴宁,丁晓燕,等.肺癌患者外周血中MDR-1及MRP基因在化疗前后的表达及意义[J].实用肿瘤学杂志,2015,29(2):127-132.
3 Maiese K.mTOR:Driving apoptosis and autophagy f,or neurocardiac complications of diabetes mellitus[J].World J Diabetes,2015,6(2):217-224.
4 Mairinger F,Vollbrecht C,Halbwedl I,et al.Reduced folate carrier and folylpolyglutamate synthetase,but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma[J].J Thorac Oncol,2013,8(5):644-653.
5 Giovannetti E,Toffalorio F,De Pas T,et al.Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer:a changing landscape?[J].Pharmacogenomics,2012,13(9):1073-1086.
6 Park S,Keam B,Kim SH,et al.Pemetrexed singlet versus nonpemetrexed-based platinum doublet as second-line chemotherapy after first-line epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor failure in non-small cell lung cancer patients with EGFR mutations[J].Cancer Res Treat,2015,2(16)[Epub ahead of print].
7 Zhang D,Ochi N,Takiqawa N,et al.Establishment of pemetrexed-resistant non-small cell lung cancer cell lines[J].Cancer Letters,2011,309(2):228-235.
8 Gonen N,Assaraf YG.Antifolates in cancer therapy:structure,activity and mechanisms of drug resistance[J].Drug Resist Updat,2012,15(4):183-210.
9 Rothbart SB,Racanelli AC,Moran RG.Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas[J].Cancer Research,2010,70(24):10299-10309.
10 Racanelli AC,Rothbart SB,Heyer CL,et al.Therapeutics by cytotoxic metabolite accumulation:Pemetrexed causes ZMP accumulation,AMPK activation,and mTOR inhibition[J].Cancer Research,2009,69(13):5467-5474.
11 Stenesen D,Suh JM,Seo J,et al.Adenosine nucleotide biosynthesis and AMPK regulate adult life span and mediate the longevity benefit of caloric restriction in flies[J].Cell Metabolism,2013,17(1):101-112.
12 Chappell WH,Steelman LS,Long JM,et al.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors:rationale and importance to inhibiting these pathways in human health[J].Oncotarget,2011,2(3):135-164.
13 Zhang W,Lei P,Dong X,et al.The new concepts on overcoming drug resistance in lung cancer[J].Drug Des Devel Ther,2014,6(8):735-744.
14 Wang S,Amato KR,Song W,et al.Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways[J].Mol Cell Biol,2015,35(7):1299-1313.
15 Kawabata S,Chiang CT,Memmott RM,et al.Rapamycin decreases expression of thymidylate synthase and enhances the response to pemetrexed in preclinical studies and a Phase I/II clinical study of subjects with non-small cell lung cancer[J].Cancer Research,2014,74(19):2927-2927.
16 Yang M,Fan WF,Pu XL,et al.Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma[J].Oncology Letters,2014,7(1):227-232.
17 Chen KC,Yang TY,Wu CC,et al.Pemetrexed induces S-phase arrest and apoptosis via a deregulated activation of Akt signaling pathway[J].PloS one,2014,9(5):e97888.
18 周永芳,李晓莉.与肺癌密切相关的细胞信号传导通路研究进展[J].实用肿瘤学杂志,2013,27(6):563-567.

[1]	刘志强,褚艳杰,刘静,王彦博. m白术内酯Ⅰ通过TLR4/MyD88通路调控肺癌A549细胞增殖侵袭的研究[J]. 实用肿瘤学杂志, 2019, 33(3): 228-232.
[2]	邵佳月, 孙秀威. 大蒜素联合5-FU对结肠癌HT-29细胞凋亡的影响及机制[J]. 实用肿瘤学杂志, 2018, 32(4): 289-292.
[3]	孙丽娜, 赵晓迪综述, 卢瑗瑗, 王新审校. LncRNA与胃肠道肿瘤化疗耐药的研究进展[J]. 实用肿瘤学杂志, 2017, 31(5): 448-453.
[4]	刘乙澍综述, 曲国蕃审校. mTOR信号通路与滑膜肉瘤研究进展[J]. 实用肿瘤学杂志, 2017, 31(5): 477-480.
[5]	曾玉兰,刘洋洋,梁金燕,谷飞飞,刘莉. 免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 353-358.
[6]	黄剑，庞慧，宋雨航综述，蔡莉审校. microRNA在乳腺癌耐药中的作用[J]. 实用肿瘤学杂志, 2017, 31(3): 272-276.
[7]	于飞, 胡晶(综述), 陈雪松(审校). 乳腺癌他莫昔芬耐药机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(2): 160-164.
[8]	段佩雯, 赵苗苗综述, 王松坡审校. NF-κB对大肠癌发生发展的影响及其相关治疗的研究现状[J]. 实用肿瘤学杂志, 2017, 31(1): 43-47.
[9]	赵郁，朱晓婷，王轶楠. ω-3多不饱和脂肪酸诱导多发性骨髓瘤细胞凋亡及抗增殖机制的研究[J]. 实用肿瘤学杂志, 2016, 30(6): 516-522.
[10]	任婷婷，邢影，综述，孟庆威，审校. 细胞自噬与肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2016, 30(6): 543-546.
[11]	赵玲, 贺金奇, 白淑平, 郭丽, 王晓红. EZH2过表达在MCF-7获得性耐药中的作用[J]. 实用肿瘤学杂志, 2016, 30(2): 123-127.
[12]	池淑琦综述, 汪宏波审校. 长链非编码RNA与肿瘤耐药性的研究进展[J]. 实用肿瘤学杂志, 2016, 30(2): 150-153.
[13]	罗京, 张婷, 黄卉综述, 杨丹审校. 软骨肉瘤化疗耐药机制[J]. 实用肿瘤学杂志, 2016, 30(2): 176-179.
[14]	潘夏综述, 江建平审校. Alectinib在非小细胞肺癌治疗中的研究进展[J]. 实用肿瘤学杂志, 2016, 30(1): 75-79.
[15]	张伟,吴瑾. 肿瘤多药耐药机制的研究进展[J]. 实用肿瘤学杂志, 2015, 29(4): 364-367.

AICARFT及mTOR在人肺腺癌亲本株A549及培美曲塞耐药株A549/PEM的表达及意义

The expression and significance of AICARFT and mTOR in pemetrexed resistant human lung adenocarcinoma cancer cell line A549/PEM

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价